Most patients with stage I, II, or III melanoma indicated to be unfamiliar with any mutations present in their tumour, compared to 46% of patients with stage IV melanoma and 53% of carers who indicated that a BRAF mutation had been found in the tumour. Here, BRAF is linked to neoplasm.